Mimedx (MDXG) Convertible Debt (2011 - 2012)
Mimedx recorded quarterly Convertible Debt of $4.0 million in Q4 2012, up 14.85% quarter-over-quarter from $3.5 million in Q3 2012, and up 46.19% year-over-year from $2.7 million in Q1 2012.
Mimedx's Convertible Debt history runs 2 years deep, the most recent figure standing at $4.0 million for Q4 2012.
- In Q4 2012, Convertible Debt rose 46.19% year-over-year to $4.0 million; the TTM figure through Dec 2012 stood at $4.0 million (up 46.19% YoY), while the FY2012 annual figure was $4.0 million, up 46.19% from the prior year.
- Convertible Debt came in at $4.0 million for Q4 2012 at Mimedx, up from $3.5 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $4.0 million in Q4 2012 to a low of $959209.0 in Q2 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 4.01 Mn |
| Sep 30, 2012 | 3.49 Mn |
| Jun 30, 2012 | 3.24 Mn |
| Mar 31, 2012 | 3.02 Mn |
| Dec 31, 2011 | 2.74 Mn |
| Jun 30, 2011 | 959,209.00 |